SCHEMBL5092004

SCHEMBL5092004

Nc1ccccc1N1CCC(F)(F)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.60
ADRA2C P18825 1/20 0.56
GAA P10253 5/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
USP2 O75604 2/20 0.53
KDM4E B2RXH2 2/20 0.41
FFAR2 O15552 2/20 0.40
HTT P42858 3/20 0.38
TP53 P04637 1/20 0.38
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
LGMN Q99538 1/20 0.35
ADRB2 P07550 1/20 0.35
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
S100B P04271 2/20 0.34
ALOX15 P16050 2/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30667429 0.89 KEAP1 (0.52) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL23123094 0.87 KEAP1 (0.44) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL29446066 0.84 KEAP1 (0.42) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL22964660 0.84 KEAP1 (0.42) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL23043597 0.82 KEAP1 (0.62) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL11775877 0.81 ADRA2C (0.79) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL23152040 0.81 ADRA2C (0.79) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL23043615 0.81 ADRA2C (0.61) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL23043708 0.79 KEAP1 (0.63) KEAP1ADRA2CGAAMEN1KMT2A
SCHEMBL484010 0.77 KEAP1 (0.95) KEAP1ADRA2CGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP claimed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US claimed
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS LIBRA THERAPEUTICS, INC. 2023-01-12 US disclosed
US-20220315548-A1 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 2022-10-06 US disclosed
WO-2021041866-A1 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-03-04 WO disclosed
US-7427683-B2 c-fms kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-09-23 US disclosed
EP-1812425-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-01 EP disclosed
WO-2006047479-A2 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed
US-20050131022-A1 C-fms kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315548-A1 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF MCOLN1, MCOLN2, MCOLN3 KEAP1 3912/4885ADRA2C 2427/4885GAA 154/4885
US-20050131022-A1 C-fms kinase inhibitors FLT3, FES, FGR KEAP1 3004/4885ADRA2C 2985/4885GAA 4542/4885
US-20230010299-A1 HETEROCYCLIC TRPML1 AGONISTS TRPM7, TRPM2, TRPM5 KEAP1 1775/4885ADRA2C 750/4885GAA 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.